The oligonucleotide drug development pipeline is rapidly expanding, featuring over 600 candidates from more than 200 companies including Novartis, Amgen, and Alnylam. These therapies target genetic diseases, cancers, and rare disorders using advanced mechanisms like RNA interference and antisense oligonucleotides. Key drugs such as Pelacarsen and Olpasiran are in late-stage trials, signaling potential new treatments soon. The market is competitive, driven by innovation in delivery platforms and partnerships, with regulatory approvals and financing rounds supporting progress.
Over 25 pharmaceutical companies are actively developing more than 30 drugs for sepsis treatment, with several therapies in late-stage clinical trials. This robust pipeline includes innovative approaches like immunomodulators and precision medicine t...
AI technology is revolutionizing pharmaceutical packaging by enabling zero-defect production and meeting strict regulatory standards. Automated AI inspection systems deliver a 315% ROI with payback under four months, improve throughput by 32%, and re...
The personalized medicine market is projected to grow from USD 524 billion in 2025 to over USD 1 trillion by 2034, fueled by advances in genomics, biomarker diagnostics, and AI-powered data analytics. This growth is driven by rising chronic diseases ...
